Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Gremubamab, an antibody targeting PcrV type III secretion system × Polysaccharide synthesis locus (Pseudomonas).

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Gontivimab, an antibody targeting Respiratory Syncytial Virus Glycoprotein F.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Avdoralimab, an antibody targeting C5AR1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Zansecimab, an antibody targeting ANGPT2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Melrilimab, an antibody targeting IL1RL1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Izuralimab, an antibody targeting ICOS × PD-1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Alomfilimab, an antibody targeting ICOS.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Golocdacimab, an antibody targeting OLR1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Galegenimab, an antibody targeting HTRA1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tobemstomig, an antibody targeting PD-1 × LAG-3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tarperprumig, an antibody targeting ALB × CFP.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Perenostobart, an antibody targeting ENTPD1.